Search

Your search keyword '"Provent S"' showing total 13 results
Start Over Author "Provent S"
13 results on '"Provent S"'

1. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

Author

Selle, F., Wittnebel, S., Biron, P., Gravis, G., Roubaud, G., Bui, B.N., Delva, R., Bay, J.O., Fléchon, A., Geoffrois, L., Caty, A., Soares, D.G., de Revel, T., Fizazi, K., Gligorov, J., Micléa, J.M., Dubot, C., Provent, S., Temby, I., Gaulet, M., Horn, E., Brindel, I., and Lotz, J.P.

Published
2014
Full Text
View/download PDF

5. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial

Author

Lotz, J.-P., Bui, B., Gomez, F., Théodore, C., Caty, A., Fizazi, K., Gravis, G., Delva, R., Peny, J., Viens, P., Duclos, B., De Revel, T., Curé, H., Gligorov, J., Guillemaut, S., Ségura, C., Provent, S., Droz, J.-P., Culine, S., and Biron, P.

Published
2005
Full Text
View/download PDF

8. The TAXIF II Protocol Final Results: A Phase II Trial of High-Dose Chemotherapy Supported by Haematopoietic Stem Cell Transplantation in Patients with Disseminated Germ-Cell Tumors Failing Chemotherapy and with Adverse Prognostic Factors

Author

Selle, F., primary, Fizazi, K., additional, Biron, P., additional, Gravis-Mescam, G., additional, Bui, B., additional, Bay, J., additional, Flechon, A., additional, Dubot, C., additional, Caty, A., additional, Burcoveanu, D., additional, Delva, R., additional, de Revel, T., additional, Miclea, J.M., additional, Gaulet, M., additional, Horn, E., additional, Provent, S., additional, Temby, I., additional, Brindel, I., additional, Khalil, J., additional, Gligorov, J., additional, and Lotz, J.-P., additional

Published
2012
Full Text
View/download PDF

10. 991 Serial monitoring of serum HER-2 extracellular domain (H-ECD) during herceptin-taxol chemotherapy (CT) for metastatic breast cancer (MBC) pts: preliminary results from the French experience (HER.ME.S protocol)

Author

Lotz, J.P., primary, Brault, D., additional, Le Lay, K., additional, Campione, M., additional, Kerbrat, P., additional, Hocini, H., additional, Maindrault-Goebel, F., additional, Tsé, C., additional, Provent, S., additional, and Launois, R., additional

Published
2003
Full Text
View/download PDF

12. A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.

Author

Selle F, Pautier P, Lhommé C, Viens P, Fabbro M, Lokiec F, Gligorov J, Richard S, Provent S, Soares DG, and Lotz JP

Subjects
Adenocarcinoma, Clear Cell mortality, Adenocarcinoma, Clear Cell pathology, Adenocarcinoma, Mucinous mortality, Adenocarcinoma, Mucinous pathology, Adolescent, Adult, Aged, Cohort Studies, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cystadenocarcinoma, Serous mortality, Cystadenocarcinoma, Serous pathology, Endometrial Neoplasms mortality, Endometrial Neoplasms pathology, Female, Follow-Up Studies, Humans, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Prognosis, Salvage Therapy, Survival Rate, Topotecan administration & dosage, Young Adult, Adenocarcinoma, Clear Cell therapy, Adenocarcinoma, Mucinous therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cystadenocarcinoma, Serous therapy, Endometrial Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Ovarian Neoplasms therapy
Abstract

Background: Dose-intensive chemotherapy with hematopoietic stem cell transplantation has been evaluated as a salvage treatment for recurrent ovarian cancer, but its benefit has not yet been demonstrated. In a previous phase I trial, we reported the feasibility of administering topotecan as a salvage regimen., Methods: Twenty-one patients were treated with escalating doses of topotecan associated with a fixed dose of cyclophosphamide., Results: The maximum tolerated dose was established at 9.0 mg/m2 on a 5-day regimen, analogously to what was reported for topotecan monotherapy. One toxic death from septic shock and multiorgan failure occurred. Although hematopoietic toxicities were overcome by peripheral blood stem cell transplantation, superior nonhematological toxicities were observed as compared to the initial trial., Conclusion: Response rates were generally short and survival rates were poor. Results of the ITOV 01bis study demonstrate that, in the setting of recurrent ovarian cancer, intensive chemotherapy based on topotecan-cyclophosphamide association is not currently clinically indicated., (© 2015 S. Karger AG, Basel.)

Published
2016
Full Text
View/download PDF

13. In situ activity of gelatinases during Lewis lung carcinoma progression.

Author

Tucker GC, Ferry G, Provent S, and Atassi G

Subjects
Animals, Collagenases metabolism, Disease Progression, Enzyme Precursors metabolism, Lung Neoplasms pathology, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Metalloendopeptidases metabolism, Mice, Muscle, Skeletal enzymology, Gelatinases metabolism, Lung Neoplasms enzymology, Lung Neoplasms physiopathology
Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results